OncoMatch/Clinical Trials/NCT07486089
Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Is NCT07486089 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Dual-target CAR-NK cells (EB-DT-CAR-NK) and Lymphodepleting chemotherapy for breast cancer (locally advanced or metastatic).
Treatment: Dual-target CAR-NK cells (EB-DT-CAR-NK) · Lymphodepleting chemotherapy — This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1, and in some TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Biomarker criteria
Required: HER2 (ERBB2) expression (expression of at least one candidate target antigen)
expression of at least one candidate target antigen (HER2/ERBB2, MUC1, or ROR1)
Required: MUC1 expression (expression of at least one candidate target antigen)
expression of at least one candidate target antigen (HER2/ERBB2, MUC1, or ROR1)
Required: ROR1 expression (expression of at least one candidate target antigen)
expression of at least one candidate target antigen (HER2/ERBB2, MUC1, or ROR1)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: standard therapies appropriate for the disease subtype and line of therapy
Progression after, intolerance to, or ineligibility for standard therapies appropriate for the disease subtype and line of therapy
Cannot have received: gene-modified cellular therapy (CAR-T, CAR-NK)
Exception: within 6 months or unresolved grade ≥ 2 toxicity from prior cellular therapy
Prior gene-modified cellular therapy (e.g., CAR-T or CAR-NK) within 6 months or unresolved grade ≥ 2 toxicity from prior cellular therapy
Lab requirements
Blood counts
anc ≥ 1.0 x 10^9/l; platelets ≥ 75 x 10^9/l; hemoglobin ≥ 8 g/dl
Kidney function
creatinine clearance ≥ 50 ml/min
Liver function
ast/alt ≤ 3x uln (≤ 5x with liver metastases); total bilirubin ≤ 1.5x uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ 45% and no uncontrolled cardiac arrhythmia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07486089 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene-modified cellular therapy disqualifies patients from enrollment.
Does this trial require ERBB2?
Yes, ERBB2 expression is a required biomarker for enrollment.
Does this trial require MUC1?
Yes, MUC1 expression is a required biomarker for enrollment.
Does this trial require ROR1?
Yes, ROR1 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify